Stay updated on Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page.

Latest updates to the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page
- Check5 days agoChange DetectedDifference0.2%
- Check12 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed information about a phase II trial for cabozantinib in treating osteosarcoma and Ewing sarcoma, while adding new identifiers and classifications related to these conditions.SummaryDifference52%
- Check19 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check27 days agoChange DetectedThe page has been updated to include information on Soft Tissue Sarcoma while removing references to Osteosarcoma. Additionally, the revision number has been updated from v2.14.2 to v2.14.3.SummaryDifference0.1%
- Check34 days agoChange DetectedDifference0.2%
- Check63 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
Stay in the know with updates to Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page.